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The pharmaceutical industry comprises establishments 
primarily engaged in manufacturing drugs, medicines 
and related products for human or animal use. 
Nowadays, bio pharmaceutical corporations are facing 
serious inefficiencies in their drug discovery process. 
The drug discovery process consists of four phases. 
These are research phase (average 3 years), pre-
clinical testing phase (average 1 year), clinical trial 
testing phase involving human patients (average 10 
years) and regulatory approval phase (average 2 
years). Undoubtedly, research is the step in which 
substantial risks are being taken. During this process, 
researchers develop tests to screen libraries of 
chemical compounds against therapeutic targets, 
evaluate the amount of a drug required to effectively 
treat the disease, study the extent to which a drug 
interacts only with the target, assess the presence and 
significance of any harmful side effects and design the 
way the drug is going to be administered to patients.  
  
The pharmaceutical companies are expecting to cut 
the drug discovery time line by half, triple the number 
of compounds delivered to develop new drugs and 
achieve double-digit growth rates by exploiting the 
‘Blockbuster’ drug/therapy strategy. Unfortunately, 
‘Bio Pharma’ has not been able to fulfil those 
expectations. The average time line for a new drug 
candidate to be on the market is still around sixteen to 
twenty years. There is a shortage in new drug 
candidates availability, which has not been solved by 
increasing the Research and Development spending. 
The ‘Blockbuster’ strategy has been disappointing, 
only one in five new launches is considered 
significant (generating revenue exceeding $500 
million per year).  
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Drug discovery is a long journey fraught with risks as 
well as painstaking research and testing. The 
pharmaceutical companies are willing to invest in any 
process that could accelerate the drug discovery 
development. Typically, a new drug addressing a 
disease previously without an effective remedy can 
generate revenue of $1Billion per year.  The 
pharmaceutical industry is a classic winner-takes-all 
industry as the first-mover with a new drug usually 
gets over 75% of the market. Given that situation 
there is no doubt that in pharmaceutical corporations 
new operating structures to enable collaborative 
relationships and cost-effective management are 
needed.  
 
It is generally agreed that efficiency, productivity and 
quality are the main drivers for the pharmaceutical 
industry. However, there is a tendency to 
underestimate the impact that R&D operations, 
project prioritisation and partnership strategies have in 
the company output.  
 
Research & Development Operations 
 
Research and Development operations constitute a big 
issue in the operating model of pharmaceutical 
companies. The objective of this unit is to investigate, 
evaluate and discover new drug candidates to cure, 
treat or prevent current diseases.  At present, these 
departments are undergoing considerable changes 
associated to the molecular biology revolution, a 
thriving discipline that is providing higher numbers of 
possible therapeutic targets that are not yet validated. 
The problem then is shifted to assay development, 
where one of the most serious bottlenecks occurs. 
There is an unmet need for high throughput assays to 
be used in the validation of the therapeutic targets. If 
that problem is solved, then the drug discovery 
process can change from a linear process to an 
iterative process in which target validation runs in 
parallel with drug discovery or drug optimisation 
activities. Given this, it is important to take into 
account that research and development operations 
need to incorporate internal and external data.  This is 
particularly the case with genomic information, which 
is so vast and complex that cannot be efficiently 
managed solely in-house.  
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Project prioritisation is concerned with allocating the 
company resources according to the importance of 
each project. A large number of pharmaceutical 
companies organise their portfolio of projects by 
using a similar set of criteria. The typical ones 
consider commercial value of the possible drug that 
the company will develop, risk of undertaking an 
alternative approach to drug identification and the 
competitive situation of the company in the specific 
niche of the health industry. A small number of 
companies also consider the novelty of the drug or the 
therapy that are willing to develop, the time to clinical 
trials and the advantageous or disadvantageous 
position of the company concerning the intellectual 
property that can be obtained in each project. 
Unfortunately, project prioritisation is not being 
carried out in the best way possible. It is often used to 
track resource utilisation rather than forecasting or 
modelling the better way to fit each project into the 




In today's market, bio pharmaceutical companies are 
facing increasing challenges in all aspects of their 
day-to-day business. It is widely recognised that there 
is a need to bring more drugs onto the market, quicker 
and at a reduced cost. One option to overcome that 
situation is carrying out technology-oriented mergers, 
acquisitions, and company alliances. It is suitable to 
consider that by increasing the firm size through 
partnerships and alliances does not guarantee by any 
means that the company performance would be 
successful. The need to administrate across multiple 
sections of the company increases the management 
complexity, particularly slowing the processes of 
decision making. Some studies remark that 
pharmaceutical companies should re-evaluate the idea 
that 'Big is Better' and integrate through cooperative 
research the critical mass needed in the vital areas of 
drug development. With that kind of partnerships bio 
pharmaceuticals can experiment emerging 
technologies before bringing them in-house. The idea 
is shifting from straightforward contracts and licences 
to 'invasive' deals in which people, technology and 
strategies are shared. In most cases, the innovation 
needed to fuel the growth expectations of 
pharmaceutical companies is occurring in the 
biotechnology sector where 'Bio Pharma' can have 
access to critical capabilities in a relatively short 
period of time. Partnership strategies are becoming a 
big issue in the health and pharmaceutical industry. It 
is clear that a competitive pharmaceutical company 
cannot stay in the top league if it only grows 
internally. It must combine crucial capabilities and 
multidisciplinary professionals.  
 
In conclusion, it seems that the future of bio 
pharmaceutical companies depends on new portfolio 
management strategies. The idea is to change the 
performance of the company by implementing 
integrated rather than isolated solutions. In other 
words, consider technical, cultural, strategic and 
organisational issues that may occur if a management 
change happens.  
 
In most of the bio pharmaceutical companies there is a 
tendency to create value via knowledge management 
and intellectual protection. It is now widely accepted 
that these corporations should retain in-house only 
those activities where their specific expertise truly 
adds value to the company. The idea is to use 
alliances to gain critical mass, incorporate 
technological breakthroughs and improve 
shareholders value. Nowadays, as the number of 
biotechnology products in clinical trials increases, 
pharmaceutical firms are progressively looking at 
biotechnology companies to fill their pipelines. It is 
now generally recognised that drugs developed in 
biotech-pharmaceutical alliances perform better than 
products developed solely in-house by biotech or 
pharmaceutical firms. That evidence confirms that co-
development adds value that is sufficient to outweigh 
any moral hazard problems that result from sharing 
development responsibilities.  
 
It should be considered that biotechnology and 
pharmaceutical companies are to some extent 
complementary. Biotechnology firms are mainly 
concerned with the generation of new drugs using 
breakthrough technologies, while pharmaceutical 
corporations are usually cash-abundant and can buy 
innovation from Biotechs. Then, Bio Pharma can 
effectively take those novel drugs and navigate them 
through the regulatory affairs conundrum and 
subsequently bring them onto the global market place 
successfully.  
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With the time and costs involved in drug discovery 
and development, it is vital that Biotechnology and 
Pharmaceutical companies come up with 
appropriately balanced deals where the contributions, 
rewards and strengths of each collaborating party are 
clearly recognized. This is especially relevant as 
biotech and pharmaceutical companies are turning 
with increasing frequency to in-licensing and 
collaboration agreements. 
 
On the whole, the continued expansion of the global 
bioscience sector drives a clear demand for the 
development of scientists at postgraduate level skilled 
in biotechnology and business. There is a shortage of 
skilled scientists with business expertise who can take 
an active role in solving the challenges highlighted 
above. 
 
The following table summarizes a number of 
postgraduate programs that combine science and 
business, which may prove of great value to 
enthusiastic bio-entrepreneurs looking to play a part 
of the future of BioPharma. 
 
  
Selected bio entrepreneurial 
programs Location Program URLs 
Institute of Biotechnology at the 
University of Cambridge (Cambridge, 
UK) 
Masters in Bioscience Enterprise http://www.bio.cam.ac.uk/bioenterprise
/   
Graduate School of Business, San 
Diego State University (San Diego, CA, 
USA) 
Joint PhD/MBA in Life Sciences http://www-
rohan.sdsu.edu/~cba/grad/phd.html 
College of Management at the Georgia 
Institute of Technology (Atlanta, GA, 
USA) and the School of Law at Emory 
University (Atlanta, GA, USA)  
Technological Innovation: Generating 
Economic Results (TI:GER) graduate 
certificate program  
http://mgt.gatech.edu/tiger/  
Center for Bioentrepreneurship, 
University of California, San Francisco 
(CA, USA) 
Courses and seminars, planning a certificate 
program 
http://www.ucsf.edu/cbe/  
The William J. von Liebio Center for 
Entrepreneurism and Technology 
Advancement, Jacobs School of 
Engineering, University of California, 
San Diego (La Jolla, CA, USA)  
Courses, project support, networking http://www.vonliebio.ucsd.edu/  
Universidad de Torcuato di tella 
(Argentina) 
Master de Biotecnología y negocio http://www.utdt.edu/download.php?fna
me=_118425733757165500.pdf 
Instituto Empresa (Spain) Master in Biotechnology Management http://www.master-
biotechnology.ie.edu/  
Macquarie University (Australia) Master of Biotechnology with Master of 







Oxford Brookes University (United 
Kingdom) 
Biotechnology with Business  
MSc / PGDip 
http://www.brookes.ac.uk/studying/cou
rses/postgraduate/2007/biotech_bus 
RMIT University (Australia) Master of Biotechnology and Business 






Stanford Biodesign Network and 
Stanford Entrepreneurship Network, 
Stanford University (Palo Alto, CA, 
USA) 
Forum, networking http://mdn.stanford.edu/  
http://www.stanford.edu/group/eship/  
Source: University websites. 
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